KAIST illuminates the eyes of humanoid robots with minimal memory
Reports and Proceedings
Updates every hour. Last Updated: 19-Jun-2026 21:15 ET (20-Jun-2026 01:15 GMT/UTC)
KAIST-MIT-Microsoft Develop AI Technology to Restore Compressed Visual Information to High Resolution Without Additional Training
GPU (Graphics Processing Unit) memory efficiency improved by up to 16 times... expected to accelerate commercialization of humanoid robots and on-device AI
Following paper acceptance at 'CVPR 2026', the world's most prestigious conference in artificial intelligence, global technological prowess and research reliability were proven by winning the 'CVPR Compute Gold Star' and being selected as 'Transparency Champion'
Systematic reviews and meta-analyses form the basis for healthcare and health policy, but access to the data on which the results are based is often lacking. This is shown in a new policy forum article from Karolinska Institutet published in the journal PLOS Medicine.
Cleveland Clinic researchers are unlocking quantum computing’s full potential through the creation of a new computing paradigm inspired by the human brain. Fabio Cumbo, PhD, Research Associate in the lab of Daniel Blankenberg, PhD, Associate Staff, Computational Life Sciences, is developing the model, called quantum hyperdimensional computing (QHDC).
Dr. Cumbo published the first-ever implementation of QHDC on two distinct experiments in Nature’s npj Unconventional Computing.
Foundation and multimodal models now match expert-level performance on many diagnostic, prognostic, and biomarker tasks in pathology. Yet only a handful of AI systems are used in routine clinical practice, and the products that have reached patients differ substantially from research prototypes. We define this mismatch as the adoption paradox of computational pathology.
We first survey the technical landscape from task-specific deep learning to large unimodal foundation models, multimodal systems, and early agentic architectures. We then examine what has actually entered the clinic, identifying four product archetypes (digital pathology platforms, population scale cytology screening, assistive detection in surgical pathology, and quantitative immunohistochemistry scoring). Using a three stage maturity model algorithmic capability (Stage 1), system integration (Stage 2), and institutional adoption (Stage 3), we analyze the structural barriers that gate each transition.
Three interconnected barriers explain most of the gap: (1) Data and infrastructure fragility [(pre-analytical variability, scanner-induced domain shift, format fragmentation, annotation scarcity, manual quality control (QC)]; (2) Workflow misalignment (cognitive rhythm of pathologists, automation bias, scenario-dependent latency); (3) Institutional trust deficits (shallow interpretability, incomplete prospective validation, unclear reimbursement, unsettled liability, and regulatory gaps for generative/adaptive systems).
We outline system-level pathways for each stage, including infrastructure first, AI, workflow-embedded intelligence, and adaptive governance. Our central claim is that the next phase of progress will depend less on architectural novelty than on the slower institutional work that turns capability into clinical benefit. The framework provides an actionable lens for regulators, developers, and healthcare organizations to diagnose why a given AI system remains a prototype and what is needed to move it into routine use.
The third annual Cleveland Discovery and Innovation Forum, hosted by Cleveland Clinic and IBM, highlighted progress in applying quantum computing and AI to healthcare and life sciences research. The forum brought together global leaders in healthcare, science and technology to share insights into how advanced computing is accelerating discovery and shaping the future of patient care.
The one-day event, held today on Cleveland Clinic’s Main Campus, featured more than 30 speakers from academia, industry, foundations, venture capital and government.Researchers at Klick Labs are launching a series of clinical studies with Mayo Clinic in Florida exploring the use of novel vocal biomarkers in connection with a number of chronic diseases and serious health conditions. The new research collaboration plans to include scientists from Klick Labs’ vocal biomarker practice, along with Mayo Clinic Principal investigators across several fields, led by Vivek Kumbhari, MD, PhD..